Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Teriflunomide – API and Licensing Agreements for Tablets Available
Details : The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Product Name : Teriflunomide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable